Services Keytruda Injection Supplier

Keytruda Injection Supplier

Derek Clarke is recognised as a Keytruda Injection supplier.

Keytruda (prembolizumab, Merck) is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

Keytruda is the first approved drug that blocks the PD-1 cellular pathway, which restricts the body’s immune system from attacking melanoma cells. The drug is administered as an intravenous infusion every three weeks.

The US Food and Drug Administration (FDA) granted Keytruda breakthrough therapy designation on the basis of demonstrating preliminary clinical evidence that the drug may offer a substantial improvement over available therapies. Keytruda was also granted priority review and orphan product designation.

Keytruda’s efficacy was established in 173 clinical trial participants with advanced melanoma whose disease progressed after prior treatment. If half of the clinical trial participants given the recommended dose of 2mg/kg, tumours shrank in 24% of people. This effect lasted for at least 1.4 to 8.5 months and continued beyond this period in most patients. The tumours shrank in a similar percentage of patients given the 10 mg/kg dose.

Keytruda’s safety was established in the trial population of 411 participants with advanced melanoma. The most common side effects of Keytruda were fatigue, cough, nausea, itchy skin (pruritus), rash, decreased appetite, constipation, joint pain (arthralgia) and diarrhea. Keytruda also has the potential for severe immune-mediated side effects.

Derek Clarke, with more than 30 years as experience as an exporter of both branded and generics medicines, is able to source and supply products, often unavailable through other sources, quickly and efficiently.

Please contact us for more information on our Keytruda injection supplies.

+44 (0) 208 952 2061